Campbell McInnes

Department of Drug Discovery and Biomedical Sciences, University of South Carolina

Affiliated withUniversity of South Carolina

Research Area

Biography

Campbell McInnes has not added Biography.
If you are Campbell McInnes and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 4	2015

Other Publications

Article	Year
Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe. Bioorganic & medicinal chemistry letters\| PubMed ID: 12182847	2002
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Current medicinal chemistry. Anti-cancer agents\| PubMed ID: 12678915	2003
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (London, England : 1993)\| PubMed ID: 12679018	2003
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (London, England : 1993)\| PubMed ID: 14656438	2003
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. Journal of medicinal chemistry\| PubMed ID: 15027857	2004
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chemistry & biology\| PubMed ID: 15123247	2004
Cambridge Healthtech Institute fourth annual conference in structure-based drug design. IDrugs : the investigational drugs journal\| PubMed ID: 15197656	2004
Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorganic & medicinal chemistry letters\| PubMed ID: 15261277	2004
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Organic & biomolecular chemistry\| PubMed ID: 15455144	2004
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 15681588	2005
Progress in the discovery of polo-like kinase inhibitors. Current topics in medicinal chemistry\| PubMed ID: 15853646	2005
Strategies for the design of potent and selective kinase inhibitors. Current pharmaceutical design\| PubMed ID: 15892678	2005
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. Journal of molecular biology\| PubMed ID: 15953616	2005
PharmaDiscovery 2005. Kinases in drug discovery. IDrugs : the investigational drugs journal\| PubMed ID: 15973561	2005
Protein structures in virtual screening: a case study with CDK2. Journal of medicinal chemistry\| PubMed ID: 16392795	2006
Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chemistry & biology\| PubMed ID: 16492568	2006
Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs : the investigational drugs journal\| PubMed ID: 16596481	2006
Improved lead-finding for kinase targets using high-throughput docking. Current opinion in drug discovery & development\| PubMed ID: 16729730	2006
Catch the kinase conformer. Chemistry & biology\| PubMed ID: 16873016	2006
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nature chemical biology\| PubMed ID: 17028581	2006
REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chembiochem : a European journal of chemical biology\| PubMed ID: 17051658	2006
Virtual screening strategies in drug discovery. Current opinion in chemical biology\| PubMed ID: 17936059	2007
Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug discovery today\| PubMed ID: 18639646	2008
Functional characterization of the RAD51D E233G genetic variant. Pharmacogenetics and genomics\| PubMed ID: 19033885	2009
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. Journal of medicinal chemistry\| PubMed ID: 19072652	2009
Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochemical pharmacology\| PubMed ID: 19167366	2009
Functional characterization and identification of mouse Rad51d splice variants. BMC molecular biology\| PubMed ID: 19327148	2009
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. ChemMedChem\| PubMed ID: 19472269	2009
Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kina... Journal of medicinal chemistry\| PubMed ID: 20146435	2010
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. Journal of medicinal chemistry\| PubMed ID: 20462263	2010
Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS chemical biology\| PubMed ID: 20843055	2010
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chemistry & biology\| PubMed ID: 21035734	2010
PLK1 as an oncology target: current status and future potential. Drug discovery today\| PubMed ID: 21601650	2011
Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells. ACS chemical biology\| PubMed ID: 22612451	2012
Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Molecular cancer therapeutics\| PubMed ID: 22848093	2012
Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly. Journal of medicinal chemistry\| PubMed ID: 23323521	2013
Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor α and β subtypes: a molecular modeling study. PloS one\| PubMed ID: 24098659	2013
Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors. Bioorganic & medicinal chemistry\| PubMed ID: 24286762	2014
Current assessment of polo-like kinases as anti-tumor drug targets. Expert opinion on drug discovery\| PubMed ID: 24819909	2014
Quantification of the effects of ionic strength, viscosity, and hydrophobicity on protein-ligand binding affinity. ACS medicinal chemistry letters\| PubMed ID: 25147617	2014
Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. Journal of medicinal chemistry\| PubMed ID: 25454794	2015
Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. Protein expression and purification\| PubMed ID: 25956535	2015